0001601830-20-000002.txt : 20201112
0001601830-20-000002.hdr.sgml : 20201112
20201112132044
ACCESSION NUMBER: 0001601830-20-000002
CONFORMED SUBMISSION TYPE: D/A
PUBLIC DOCUMENT COUNT: 1
ITEM INFORMATION: 06b
FILED AS OF DATE: 20201112
DATE AS OF CHANGE: 20201112
EFFECTIVENESS DATE: 20201112
FILER:
COMPANY DATA:
COMPANY CONFORMED NAME: RECURSION PHARMACEUTICALS, INC.
CENTRAL INDEX KEY: 0001601830
IRS NUMBER: 464099738
STATE OF INCORPORATION: DE
FISCAL YEAR END: 1231
FILING VALUES:
FORM TYPE: D/A
SEC ACT: 1933 Act
SEC FILE NUMBER: 021-375551
FILM NUMBER: 201305440
BUSINESS ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
BUSINESS PHONE: (385) 269-0203
MAIL ADDRESS:
STREET 1: 41S RIO GRANDE STREET
CITY: SALT LAKE CITY
STATE: UT
ZIP: 84101
FORMER COMPANY:
FORMER CONFORMED NAME: Recursion Pharmaceuticals, LLC
DATE OF NAME CHANGE: 20140305
D/A
1
primary_doc.xml
X0708
D/A
LIVE
0001601830
RECURSION PHARMACEUTICALS, INC.
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
(385) 269-0203
DELAWARE
Recursion Pharmaceuticals, LLC
Corporation
true
CHRISTOPHER
C.
GIBSON
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
Executive Officer
Director
Promoter
BLAKE
C.
BORGESON
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
Director
ZAVAIN
DAR
1600 EL CAMINO REAL
SUITE 290
MENLO PARK
CA
CALIFORNIA
94025
Director
ZACHARY
BOGUE
317 UNIVERSITY AVENUE
SUITE 200
PALO ALTO
CA
CALIFORNIA
94301
Director
DEAN
LI
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
Director
ROBERT
HERSHBERG
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
Director
TERRY-ANN
BURRELL
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
Director
R.
MARTIN
CHAVEZ
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
Director
MICHAEL
SECORA
41S RIO GRANDE STREET
SALT LAKE CITY
UT
UTAH
84101
Executive Officer
Promoter
Pharmaceuticals
Decline to Disclose
- 06b
true
0001601830-20-000001
2020-09-01
false
true
false
0
245896677
245896677
0
false
49
0
0
0
false
RECURSION PHARMACEUTICALS, INC.
/s/ Christopher C. Gibson
Christopher C. Gibson
Chief Executive Officer
2020-11-11